2023年1月10日，来自瑞士ISREC的Douglas Hanahan团队在Immunity杂志上发表了一篇题为 Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumorreactiveCD8+Tcellsand reprogramming macrophages 的文章，他们揭示了免疫细胞因子PD1-IL2v与抗PD-L1协同作用增强免疫治疗耐受肿瘤的...
2023年1月10日,来自瑞士ISREC的Douglas Hanahan团队在Immunity杂志上发表了一篇题为Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumorreactiveCD8+Tcellsand reprogramming macrophages的文章,他们揭示...
这种癌症对一种称为免疫检查点阻断的免疫疗法极具抵抗性,在这种免疫疗法中,患者接受一种药物(免疫检查点抑制剂),这种药物阻断通常使免疫反应不会太强但也能阻止免疫细胞(T细胞)杀死癌细胞的蛋白。相关研究结果发表在2023年1月10日的Immunity期刊上,论文标题为“Bispecific PD1-IL2v and anti-PD-L1 break tumor imm...
Interestingly, following tumor shrinkage, the PanNETs appeared to stabilize and eventually relapsed. Notably, we identified up-regulation of PD-L1 on the tumor vasculature in relapsing tumors as a potential factor in the observed adaptive resistance, which encouraged combining an anti-PD-L1 antibody ...
PD1-IL2v elicited substantial infiltration by stem-like CD8+ T cells, resulting in tumor regression and enhanced survival in mice. Combining anti-PD-L1 with PD1-IL2v sustained the response phase, improving therapeutic efficacy both by reprogramming immunosuppressive tumor-associated macrophages and ...
2023年1月10日,来自瑞士ISREC的Douglas Hanahan团队在Immunity杂志上发表了一篇题为Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumorreactiveCD8+Tcellsand reprogramming macrophages的文章,他们揭示了免疫细胞因子PD1-IL2v与抗PD-L1协同作用增强免疫治疗耐受肿瘤的治疗...
anti-PD-1/-L1 antibodies alone or in combination with either tolerable doses of standard IL-2 or with a non-PD-1-targeted 2nd generation IL-2Rbg agonist currently in clinical development, and thus mediate significantly superior anti-tumor efficacy at well tolerated drug doses. PD1-IL2v is ...